Sequana Medical KOL Webinar on the impact of Refractory or Recurrent Liver Ascites on Patients and Healthcare systems and the potential for alfapump® therapy in NASH-related Ascites
|DATE:||July 15, 2021|
|TIME:||12:00 AM EDT|
About The Event
The webinar will feature:
-Testimonial from a patient living with refractory ascites
-Presentations by Key Opinion Leaders (KOLs) Hugo E. Vargas, M.D. (Mayo Clinic) and Grace Knuttinen, M.D., Ph.D. (Mayo Clinic), who will discuss the impact of ascites on patients’ quality of life and the limitations of current treatment options. They will also share their experience with the alfapump implantation and its potential in the treatment paradigm for these patients
-Q&A session with the KOLs and Sequana Medical management
Ascites is the most common reason for hospitalization of patients with advanced liver disease and is forecast to grow dramatically driven by NASH-related cirrhosis. Sequana Medical’s alfapump has been granted FDA breakthrough device designation for the treatment of recurrent or refractory ascites due to liver cirrhosis.
The alfapump is a fully implantable pump system that moves ascites from the peritoneal cavity into the bladder, where it is passed naturally from the body through urination. The alfapump is approved in Europe and POSEIDON, the North American pivotal study to support regulatory approval in the US and Canada is underway. Positive interim data from the POSEIDON study were reported in November 2020 with further interim data expected in Q2 2021 and primary endpoint data in Q2 2022.